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Abstract Non-Hodgkin lymphoma of Waldeyer’s ring con-
stitutes a small percentage of cases of palatine tonsil malig-
nancies and its precise etiology remains unknown. RCAS1
(receptor cancer-binding antigen expressed on SiSo cells)
has been demonstrated to be associated with poor prognosis,
the development of lymph node metastases and participation
in tumor microenvironment remodeling. Our aim is to analyze
the potential role of RCAS1 expression in the tumor and
tumor microenvironment in the development of early-stage
palatine tonsil B-cell lymphomas. We selected 20 patients
and analyzed tissue samples from the lymphoma and tumor
microenvironment of each patient and from a reference group
of 20 patients with chronic tonsillitis. The presence of RCAS1
protein immunoreactivity was demonstrated in 65 % of the
examined tissue samples of diffuse large B-cell lymphoma
and in 25% of the analyzed stromata in which it was exhibited
by CD68-positive cells identified as macrophages and dis-
persed throughout the stroma. RCAS1 immunoreactivity in
the lymphoma tissue samples remained at a level comparable
with that of the reference and was significantly higher in these
samples than in those from the stroma. Chronic inflammation
of the palatine tonsils thus results in intensive infiltration by
various types of immune system cells and in excessive
RCAS1 immunoreactivity, both of which confirm the impor-
tant regulatory role of RCAS1 in the immune response in the
mucosa-associated lymphatic tissue of Waldeyer’s ring.
RCAS1 seems to be involved in creating tumor-induced in-
flammation in the tumor and its microenvironment.
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Introduction
Extra-nodal head and neck lymphomas are rare conditions
and the tonsils and sinuses are the most common sites of
localization (Laskar et al. 2007; Jacobs et al. 1986; Yamanaka
et al. 1985; Hart et al. 2004). Non-Hodgkin lymphoma of
Waldeyer’s ring constitutes a small percentage of cases of
palatine tonsil malignancies and its precise etiology remains
unknown. Infectious organisms, including the Epstein-Barr
virus (EBV) and human immunodeficiency virus, are increas-
ingly recognized as possible causes (Laskar et al. 2007; Hart
et al. 2004). The most common type of lymphoma found in
the palatine tonsils is the B-cell lymphoma, with DLBCL
(diffuse large B-cell lymphoma) predominating (67–96 % of
cases). The majority of these cases represent loco-regional
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instances of the disease (stages I-II; Laskar et al. 2007; Jacobs
et al. 1986; Yamanaka et al. 1985; Hart et al. 2004).
The tumor microenvironment is the tissue that supports the
tumor’s growth (Witz 2009). In our previous studies, we
analyzed and demonstrated the involvement of the tumor
microenvironment in the development of various types of
malignancies, including uterine cervical carcinoma, ovarian
cancer and pharyngeal squamous cell carcinoma, all of which
are associated with the presence of a suppressive tumor mi-
croenvironment ( Dutsch-Wicherek 2010; Dutsch-Wicherek
and Kazmierczak 2013; Dutsch-Wicherek et al. 2010, 2012,
2013; Walentowicz-Sadlecka et al. 2013; Jozwicki et al. 2011;
Galazka et al. 2012; Wicherek et al. 2012).
RCAS1 (receptor cancer-binding antigen expressed on
SiSo cells) is expressed by various human cancer cells
and during the induced apoptosis of T and B lymphocytes
and native killer (NK) cells and thus participates in tumor
escape from host immunological surveillance. In many
cases involving various types of malignant neoplasms,
RCAS1 has been demonstrated to be associated with poor
prognosis, the development of lymph node metastases and
participation in tumor microenvironment remodeling
(Dutsch-Wicherek et al. 2009, 2010, 2012; Sonoda et al.
1996, 2005, 2006, 2008, 2009; Sonoda 2011). RCAS1-
positive macrophages have been identified in the cancer
microenvironment of patients suffering from pharyngeal
and laryngeal squamous cell carcinomas and are associat-
ed with the presence of lymph node metastases (Dutsch-
Wicherek et al. 2009, 2012; Dutsch-Wicherek 2010). The
expression of RCAS1 by the tumor cells and tumor-
associated macrophages might help to create the immuno-
suppressive microenvironment in patients with parotid
gland adenocarcinoma, pharyngeal and laryngeal cancer,
ovarian cancer, uterine cancer and other types of malig-
nant neoplasms (Dutsch-Wicherek 2010; Dutsch-
Wicherek and Kazmierczak 2013; Dutsch-Wicherek
et al. 2010, 2012, 2013; Walentowicz-Sadlecka et al.
2013; Jozwicki et al. 2011; Galazka et al. 2012; Wicherek
et al. 2012; Sonoda et al. 1996, 2005, 2006, 2008, 2009;
Sonoda 2011).
The physiological role that RCAS1 of the palatine tonsils
plays in the cell regulaton and pathology of the immune sys-
tem, in B-cell lymphoma and in lymphatic system-originating
malignancies is of interest. RCAS1 expression has been ob-
served in all studied tissues of the palatine tonsils and ade-
noids, with the most intensive expression being found in the
reticular epithelium of the crypts and in the reactive centers of
the lymphatic follicles (Dutsch-Wicherek et al. 2005). The
essential regulatory role of RCAS1 in controlling erythroid
progenitor cell maturation has been established. Erythroid
progenitor cells have putative receptors for RCAS1
(RCAS1-R); high RCAS1-R expression has been found in
the cells during the early stages of erythropoietic cell
differentiation but its expression fades with cell maturation.
The lowest level of production of RCAS1 has been identified
in resting macrophages in which it nevetheless increases fol-
lowing lipopolysaccharide (LPS) stimulation. The cytolysis of
progenitor cells has been observed when these cells are co-
cultured with LPS-activated macrophages. Consequently,
macrophages have been suggested to regulate human erythro-
poiesis negatively through RCAS1 expression (Matsushima
et al. 2001; Suehiro et al. 2005). Moreover, RCAS1 regulation
has been demonstrated to play an important role in creating
maternal immune tolerance during pregnancy (Wicherek
2009; Galazka et al. 2008; Wicherek et al. 2007; Tskitishvili
et al. 2010). Thus, RCAS1 might also play an important role
in lymphatic-system-originating pathologies.
The aim of the present study is to analyze the potential role
of RCAS1 expression in the tumor and tumor microenviron-
ment in the development of early-stage palatine tonsil B-cell
lymphomas.
Materials and methods
For our study, we recruited patients with the most common
types of non-Hodgkin lymphoma occurring in adults,
namely, tonsillar DLBCL and tonsillar DLBCL with cervi-
cal lymph node involvement (i.e., stages I and II of the
disease). We selected 20 patients and analyzed tissue sam-
ples from the lymphoma and tumor microenvironment of
each paatient. The tumor microenvironment or stroma was
defined as the surrounding tissue with an area of 1 cm2
macroscopically and histologically free of malignant infil-
tration and with the distance from the tumor front not
exceeding 1 cm. The patient’s consent was obtained in
each case. Additionally, approval for the research program
was granted by the Ethical Committee of the Jagiellonian
University in Krakow (KBET/90/B/2005). All the tissue
samples were histopathologically verified. Following the
fixation of the surgically removed material in formalin,
pathological analysis with classical hematoxylin and eosin
staining techniques was performed in the Pathology De-
partment of the Jagiellonian University by two experienced
pathologists (R.T. and A.L.) working independently. First,
the tissue was fixed in a solution of 10 % formalin and then
rinsed, dehydrated and transferred through a progressively
increasing concentration of ethanol (from 50 % to absolute
alcohol) and a series of xylenes (I–III) to molten paraffin
wax. Finally, the tissue blocks were sectioned and the
resulting sections placed onto glass slides. The process
was mainly automated; however, both the paraffin embed-
ding and the cutting of the tissue samples into 3– to 4-μm-
thick sections were performed manually.
The characteristics of the patient group are presented in
Table 1.
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Reference group
As a reference group, we chose to collect palatine tonsils that
had been removed from patients suffering from recurrent ton-
sillitis (Table 2). In these tissue samples, we evaluated both the
epithelium lining of the tonsils and the lymphoid tissue.
Immunohistochemical analysis
In the present study, we analyzed the immunoreactivity levels
of various antigens in the palatine tonsil lymphoma and its
stroma. We also aimed to evaluate the distribution of the an-
tigen immunoreactivity throughout the tissue of the tumor,
including its stroma. For this reason, we chose the immuno-
histochemical method for our study. This is also the only
method that shows the actual architecture of the interaction
between the tumor and its stroma. The immunohistochemical
expression of RCAS1, CD3, CD25, CD68, CD69 and Foxp3
antigens was performed in the Pathology Department of the
Jagiellonian University. From each case, sections of 5 μm in
thickness were placed on slides and stained to visualize
RCAS1-, CD3-, CD25-, CD68-, CD69- and Foxp3-positive
cells. In all cases, immunohistochemistry was performed by
applying the Envision method with Dako Autostainer. The
samples were stained automatically by immunohistochemical
staining based on the antigen-antibody reaction. Microscopy
was performed with an Axio Zeiss microscope and the tissue
sections were evaluated under both 20× and 40× magnifica-
tion. The following antibodies were applied: mouse monoclo-
nal antibody Anti-RCAS1 (Medicaland Biological Laborato-
ries, Naka-ku Nagoya, Japan; in DAKO Antibody Diluent
with Background Reducing Components; DAKO, Denmark;
dilution 1:1000), monoclonal mouse antibody ImmunOTM
(MP Biomedicals; clone 1A12; dilution 1:1000), CD68
(DAKO, clone PG-M1; dilution 1:50), CD3 (Novocastra,
clone IF6; dilution: 1:50), CD25 (interleukin-2 Receptor,
NCL-CD25-305; Novocastra; dilution 1:25) and Foxp3
according to the manufacturer’s instructions. Visualization of
the reaction products was then performed by using AEC (3-
amino-9-ethyl-carbazole) as a chromogen (AEC Substrate
Chromogen ready-to-use; DAKO, Denmark) for 10 min at
room temperature. Sections were counterstained with hema-
toxylin and mounted in glycergel. As a positive control, a
tonsil specimen was taken for RCAS1 immunostaining. All
staining was performed with the same procedure. The primary
antibody was omitted as a negative control. RCAS1 expres-
sion in the area of the palatine tonsils in the epithelium and in
the stroma was evaluated on entire slides as follows: 0 no
reactivity; +1 weak and, when observed, any cytoplasmic (al-
so granular in paranuclear region) staining (in up to 10 % of
positive cells); +2 marked cytoplasmic staining (sometimes
together with membranous staining in 11–30 % of the cells);
+3 high expression (more than 30 % of positive cells). Vari-
able scales were used to evaluate the number of cells semi-
quantitatively, depending on their general number in the spec-
imen. CD25+, CD3+, CD68+ and CD69+ cells were thus
estimated as follows: 0 lack of positive cells; +1 single posi-
tive cells in the specimen; +2 1–5 positive cells per high power
field; +3 more than 5 positive cells per high power field.
We were able to distinguish the macrophages from the
stromal cells by their respective morphologies, i.e., by their
characteristic size, nuclear-cytoplasmic ratio and nuclear
image.
Statistical analysis
The distribution of variables in the study groups of the patients
examined with the use of the Shapiro-Wilk test showed that
each of the patients was indeed different from normal. The
statistical significance between the groups was determined
by the Kruskal-Wallis test, with one-way analysis of variance
by ranks. The Mann–Whitney U test was then used as appli-
cable. All statistical analyses were carried out with the
Statistica 8.0 software program. A P-value of <0.05 was con-
sidered as indicative of statistical significance.
Results
In the current study, the levels of immunoreactivity of CD3,
CD25, CD68, CD69, Foxp3 and RCAS1 were determined in
palatine tonsil DLBCL and its microenvironment and in the
tissues of the reference group, including the epithelium lining
Table 1 Patient group with non-Hodgkin lymphoma
Malignant non-Hodgkin B cellular lymphoma Number/age
All patients 20
Male 12
Female 8
Age range (average) of all patients in years 16–84 (62)
Age range (average) of males in years 43–81 (63.8)
Age range (average) of females in years 16–84 (59.4)
Table 2 Reference group with recurrent tonsillitis
Palatine tonsils Number/age
All patients 20
Male 12
Female 8
Age range (average) of all patients in years 14–56 (32.6)
Age range (average) of amles in years 14–56 (34.41)
Age range (average) of females in years 21–54 (29.87)
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of the tonsils and the lymphoid tissue of the palatine tonsils
derived from patients with chronic tonsillitis.
Analysis of CD3 antigen immunoreactivity
CD3 antigen immunoreactivity was observed in all the lym-
phoma tissue samples from both the tumor and the stroma and
exhibited a membrane-cytoplasmic type of expression (). CD3
antigen immunoreactivity was identified in all the lymphatic
tissue samples and was also found in 75 % of the epithelial
tissue samples. The immunoreactivity here also exhibited a
membrane-cytoplasmic type of expression and was identified
in half of the lower part of the tonsillar crypts epithelium from
the chronically inflamed palatine tonsils.
Analysis of CD25 antigen immunoreactivity
CD25 immunoreactivity was observed in 90% of the lympho-
ma tissue samples and in 50 % of the stromata samples. CD25
antigen immunoreactivity was observed in all the examined
samples of lymphatic tissue and tonsillar crypts epithelium. It
exhibited a membrane-cytoplasmic type of expression and
was most prominent in the epithelia of the tonsillar crypts.
Analysis of CD68 antigen immunoreactivity
CD68 immunoreactivity was present in 95 % of the lympho-
ma tissue samples and in 60 % of the stroma samples. CD68-
positive cells infiltrating the lymphoma and its stroma are
shown in Fig. 1. CD68 antigen immunoreactivity was ob-
served in all the samples of the lymphatic tissue of the chron-
ically inflamed palatine tonsils and in 10 % of the samples of
the palatine epithelia; this immunoreactivity was the most
prominent in the reticular epithelium of the crypts and exhib-
ited a membrane-cytoplasmic type of expression.
Analysis of CD69 antigen immunoreactivity
CD69 immunoreactivity was present in 95 % of the lympho-
ma tissue samples and in 70 % of the stroma samples. CD69
antigen immunoreactivity was observed in all the lymphatic
tissue samples of chronically inflamed palatine tonsils, al-
though not in the epithelia and it exhibited a membrane-
cytoplasmic type of expression.
Analysis of Foxp3 antigen immunoreactivity
Although Foxp3 immunoreactivity was not observed in the
stroma of the tumor, it was present in 30 % of the lymphoma
tissue samples. Foxp3 antigen immunoreactivity was ob-
served in 90 % of the samples of lymphatic tissue from the
chronically inflamed palatine tonsils but was not found in the
epithelia. It occurred in lymphocytes and demonstrated a nu-
clear type of expression.
Fig. 1 Infiltration of CD68 in
both the lymphoma and its stroma
(arrows CD68-positive
macrophages). Magnification
×40. Bar 50 μm
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Analysis of RCAS1 immunoreactivity
RCAS1 immunoreactivity was observed in 65 % of the lym-
phoma tissue samples and in 25 % of the stroma samples and
exhibited a nuclear-cytoplasmic type of expression. Dispersed
RCAS1-positive macrophages were also identified in the stro-
mata of the lymphoma tissue samples (Fig. 2).
RCAS1 immunoreactivity was observed in the palatine
tonsils of patients with chronic tonsillitis (Fig. 3) and in
60% of the lymphatic tissue samples as dispersed cells, which
were identified as macrophages, in the germinal centers of
lymphatic tissue and in all samples of the reticular epithelium
of the tonsillar crypts. RCAS1 was not found in the remainder
of the tonsillar epithelia. The type of immunoreactivity exhib-
ited was membrane-cytoplasmic. Additionally, RCAS1-
positive exfoliated epithelial cells were observed in the crypts
of the palatine tonsils and single RCAS1-positive macro-
phages were seen in the lumen of the crypts.
Analysis of immunoreactivity of antigens in lymphatic tissue
and epithelium lining of tonsils in cases of chronic tonsillitis
The results are presented in Table 3.
Fig. 2 RCAS1 (receptor cancer-
binding antigen expressed on
SiSo cells) immunoreactivity in
the lymphoma and its stroma
(arrows RCAS1-positive
macrophages). Magnification
×40. Bar 50 μm
Fig. 3 RCAS1 immunoreactivity in chronic tonsillitis. a RCAS1
immunoreactivity in the crypt epithelium (arrow). b RCAS1-positive
exfoliated epithelial cells and RCAS1-positive macrophages in the lumen
of the crypts. c RCAS1 immunoreactivity in the germinal centers (arrows
RCAS1-positive macrophages). Magnification ×40. Bars 50 μm
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Analysis of immunoreactivity of antigens studied
in lymphoma tissue samples and their microenvironment
The results are presented in Table 4.
The lymphoma tissue samples were characterized by the
significantly higher infiltration of CD68-positive macro-
phages, which were also typified by RCAS1 immunoreac-
tivity, than in the stroma tissue samples. This demonstrates
the strong suppressive profile of the tumor tissue in com-
parison with the microenvironment, as represented by
RCAS1-positive macrophages. These cells predominantly
infiltrate the tumor tissue but are also present in the micro-
environment, thereby determining the suppressive profile
of the stroma. This also reflects the tumor-stroma interac-
tion by the expression of these antigens and the presence of
RCAS1-positive macrophages. No statistically significant
differences were observed in CD69 and Foxp3 antigen
immunoreactivity.
Comparison of analyzed antigen immunoreactivity
in lymphoma tissue samples and lymphatic tissue of palatine
tonsils
The results are presented in Table 5.
Comparison of studied antigen immunoreactivity in stroma
of lymphoma and epithelium of palatine tonsils (reference
group)
The results are presented in Table 6.
Table 3 Comparison of antigen immunoreactivity in lymphatic tissue
and epithelium of palatine tonsils from patients with chronic tonsillitis
(RCAS1 receptor cancer-binding antigen expressed on SiSo cells)
Antigen Lymphatic tissue of palatine
tonsils under chronic tonsillitis,
median (Q3-Q1)
Tonsillar
epithelium,
median (Q3-Q1)
P-value
CD3 2 2 0.01
(0) (1)
CD25 2 3 0.05
(0) (1,5)
CD68 3 0 <0.0001
(0,5) (0)
CD69 3 0 <0.0001
(0) (0)
Foxp3 3 0 <0.0001
(0) (0)
RCAS1 1 3 0.0003
(2) (2)
Table 4 Comparison of immunoreactivity of analyzed antigens in
lymphoma tissue samples and their stroma (NS not significant)
Antigen Lymphoma, median
(Q3-Q1)
Stroma, median
(Q3-Q1)
P-value
CD3 2 1 0.01
(0) (1)
CD25 1 0 0.01
(0) (1)
CD68 1 0 0.02
(0) (1)
CD69 1 1 NS
(0) (1)
Foxp3 0 0 NS
(1) (0)
RCAS1 1 0 0.02
(1) (0)
Table 5 Comparison of analyzed antigen immunoreactivity in tissue
samples of lymphoma and in lymphatic tissue of palatine tonsils
Antigen Lymphoma,
median (O3-Q1)
Lymphatic tissue
of palatine tonsils,
median (Q3-Q1)
P-value
CD3 2 2 NS
(0) (0)
CD25 1 2 <0.001
(0) (0)
CD68 1 3 <0.001
(0) (0.5)
CD69 1 3 <0.001
(0) (0)
Foxp3 0 3 <0.001
(1) (0)
RCAS1 1 1 NS
(1) (2)
Table 6 Comparison of immunoreactivity of studied antigens in
lymphomatic stroma and in epithelia of palatine tonsils (reference group)
Antigen Stroma, median
(O3-Q1)
Reference group,
median (Q3-Q1)
P-value
CD3 1 2 NS
(1) (1)
CD25 0 3 <0.001
(1) (1.5)
CD68 0 0 0.01
(1) (0)
CD69 1 0 <0.001
(1) (0)
Foxp3 0 0 NS
(0) (0)
RCAS1 0 3 <0.001
(0) (2)
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Discussion
In the present study, we demonstrated the presence of RCAS1
protein immunoreactivity in 65% of the examined tissue sam-
ples of DLBCL of the palatine tonsils and in 25 % of the
analyzed stromata in which it occurred in CD68-positive cells,
which were identified as macrophages and were dispersed
throughout the stroma. The immunoreactivity of RCAS1
was statistically significantly higher in the malignant tissue
than in the stroma and the number of RCAS1-positive macro-
phages was higher in the lymphoma than in the stroma. To
our knowledge, this is the first investigation concerning the
immunoreactivity of RCAS1 in DLBC lymphoma originating
in the palatine tonsil and its stroma. The lymphoma cells, like
the cells of other types of malignant neoplasms, seem to use
the expression of RCAS1 for tumor escape from host immu-
nological surveillance. Moreover, as we have previously dis-
covered, the lymphoma seems to create the suppressive mi-
croenvironment by using RCAS1-positive macrophages in
order to control the activity of the infiltrating immune system
cells. In the literature, Ohshima et al. (2001) demonstrated the
expression of RCAS1 in Hodgkin lymphoma; they
established that RCAS1 is expressed by malignant Hodgkin
and Reed Sternberg cells of EBV-associated Hodgkin disease
and that this expression allows these cells to evade the host
immune response (Ohshima et al.2001). In T-cell leukemia,
positive staining for RCAS1 expression has been identified in
patients whose survival time is short, whereas in B-cell lym-
phoma, RCAS1 has only been identified in 1 of 8 cases.
RCAS1 has been concluded to be associated with tumor es-
cape from host immunological surveillance, especially in cells
infected by the T-lymphotropic virus type I (Muta et al. 2004).
The presence of RCAS1 in the tumor is responsible for the
process of tumor escape from host immunological surveil-
lance by the inhibition of the growth and the induction of
the apoptosis of T and B lymphocytes and NK cells (Sonoda
et al. 1996, 2005, 2006, 2008, 2009; Sonoda 2011). RCAS1
can also be shed into blood serum and pleural effusions in a
soluble form and can be a useful marker for human cancer and
the predictor of the results of the treatment (Sonoda and Kato
2014; Enjoji et al. 2004). In this way, tumor cells use RCAS1
expression for the elimination of cytotoxic immune cells from
their own microenvironment and carry out the process of se-
lective immune suppression to create the suppressive micro-
environment (Sheu et al. 1997). Physiologically, this mecha-
nism is responsible for the proper regulation of the immune
system response and this regulation seems to be disturbed in
patients with malignant neoplasms originating from the lym-
phatic system, such as lymphoma. In our study, RCAS1 im-
munoreactivity in the lymphoma tissue samples remained at a
level comparable with that of the reference group tissue sam-
ples; this level was significantly higher in these samples than
in those from the stroma. Since the palatine tonsil is a
specialized lymphatic tissue organ responsible for creating
the immune response, the proper regulation of this process is
essential and RCAS1 expression is one of the modes of such
regulation. The comparable level of RCAS1 in tissue samples
from patients with chronic tonsillitis and in lymphoma sam-
ples establishes the existence of a high level of immune cell
activity inhibition. In patients with chronic tonsillitis, RCAS1
expressionmight be induced by bacterial inflammation requir-
ing the restriction of excessive immune cell activity. By con-
trast, in cases of lymphoma, RCAS1 expression seems to be
linked with the loss of local host immune control.
This observation differs from the results obtained from ep-
ithelial malignant neoplasms, such as squamous cell carcino-
ma of the palatine tonsils, in which the expression of RCAS1
has been shown to be significantly higher in the tumor than in
the reference group tissue samples (Dutsch-Wicherek et al.
2012). Nevertheless, the detection of this expression in the
malignant cells of DLBCL of the palatine tonsils indicates
the potential role of RCAS1 protein in the phenomenon of
selective immune suppression and the creation of tumor-
induced chronic inflammation in this disease, as in other ma-
lignant diseases.
The identification of immune cell presence and activity
in our study was difficult because of the particular immu-
nohistochemistry method that we used, which allows for
the identification of only one antigen. We were therefore
unable to identify the precise type of the infiltrating cells.
In attempting to interpret this subsequently, we noted that
the lymphatic tissue of the palatine tonsils in chronic ton-
sillitis was characterized by the statistically significantly
higher infiltration of CD25-positive cells and higher Foxp3
antigen immunoreactivity than in the lymphoma sample.
Because Foxp3 and CD25 are antigens that identify Treg
cells (Whiteside 2014), a greater number of these cells are
thought to infiltrate the lymphatic tissue of the palatine
tonsils in chronic tonsillitis, i.e., under conditions of chron-
ic inflammation. We also found a statistically significantly
higher number of CD68-positive cells infiltrating the lym-
phatic tissue of the palatine tonsils in chronic tonsillitis and
a statistically significantly higher number of CD69
antigen-positive cells in the palatine tonsil lymphatic tissue
in chronic tonsillitis than in the lymphoma tissue samples.
The immune response therefore seems to be stronger in the
chronically inflamed tissue than in the lymphoma, which
seems to be only sparsely infiltrated by the activated im-
mune cells. The observed differences in the type and inten-
sity of immune infiltrate in the lymphoma and the tissue
samples of the reference group (derived from patients with
chronic tonsillitis) might reflect the nature of the lympho-
ma disease with the suppression of the immune system cell
activity and the decrease in the number of the immune
system cells infiltrating the tumor. A similar tendency
was observed in the number and activity of the infiltrating
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immune system cells between the stroma and the reference
group tissue.
In conclusion, chronic inflammation of the palatine tonsils
results in intense infiltration by various types of immune sys-
tem cells and excessive RCAS1 immunoreactivity, both of
which confirm the important regulatory role of RCAS1 in
the immune response in the mucosa-associated lymphatic tis-
sue of Waldeyer’s ring. RCAS1 seems to be involved in cre-
ating the tumor-induced inflammation in the tumor and its
microenvironment.
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